Table 2.
Bivariate Associations of baseline characteristics and 2-year mortality in the Pittsburgh derivation cohort (N=260).
| Characteristics | Odds Ratio |
95% Confidence Interval |
p-value | ||
|---|---|---|---|---|---|
| Demographics | |||||
| Age | < 0.0001 | ||||
| <35 | 0.75 | 0.22 – 2.50 | |||
| 35–44 | 0.16 | 0.15 – 1.29 | |||
| 45–54 | 1.00 | -- | |||
| 55–64 | 2.08 | 0.88 – 4.86 | |||
| > 65 | 4.63 | 1.99 – 10.77 | |||
| Male | 1.84 | 0.97 – 3.46 | 0.06 | ||
| History | |||||
| Hypertension | 0.77 | 0.16 – 3.65 | 0.74 | ||
| Coronary artery disease | 3.57 | 0.49 – 25.93 | 0.21 | ||
| Diabetes mellitus | 0.69 | 0.08 – 6.04 | 0.74 | ||
| Overlap with another connective tissue disease | 0.99 | 0.20 – 4.92 | 0.99 | ||
| Tobacco use | 0.99 | ||||
| prior vs none | 1.00 | 0.52 – 1.89 | |||
| current vs none | 0.97 | 0.42 – 2.28 | |||
| Prednisone use | never | 0.66 | |||
| prior to first visit | 0.76 | 0.42 – 1.38 | |||
| prescribed at first visit | 0.88 | 0.17 – 4.43 | |||
| Referral area (<100 miles from Pittsburgh) | 2.42 | 1.33 – 4.39 | 0.004 | ||
| Decade of diagnosis | 0.03 | ||||
| 1990s vs 1980s | 0.44 | 0.23 – 0.84 | |||
| 2000s vs 1980s | 0.43 | 0.15 – 1.20 | |||
| Physical examination findings | |||||
| Modified Rodnan skin score | 1.03 | 1.00 – 1.05 | 0.03 | ||
| Skin score > 20 (yes/no) | 1.49 | 0.80 – 2.77 | 0.21 | ||
| Skin thickness progression rate | slow | 0.02 | |||
| intermediate | 0.78 | 0.35 – 1.73 | |||
| rapid | 2.02 | 0.99 – 4.15 | |||
| Tendon friction rubs (present or absent) | 2.95 | 1.50 – 5.81 | 0.001 | ||
| Number of tendon friction rubs | 0.002 | ||||
| 1–3 vs 0 | 2.35 | 1.06 – 5.19 | |||
| > 3 vs 0 | 3.78 | 1.77 – 8.08 | |||
| Mean body mass index | 0.94 | 0.86 – 1.03 | 0.81 | ||
| Laboratory findings | |||||
| Anti-topoisomerase I antibody | 2.06 | 1.06 – 4.01 | 0.03 | ||
| Anti-RNA polymerase III antibody | 0.48 | 0.25 – 0.90 | 0.02 | ||
| Elevated sedimentation rate (ESR)*, | 0.83 | 0.43 – 1.62 | 0.59 | ||
| Anemia (present or absent) | Hgb < 12 mg/dL | 4.79 | 2.50 – 9.15 | < 0.0001 | |
| Degree of anemia | < 0.0001 | ||||
| Hgb > 12 mg/dL | 1.00 | ||||
| Hgb 10–12 mg/dL (mild) | 4.29 | 2.03 – 9.06 | |||
| Hgb < 10 mg/dL (severe) | 4.09 | 1.92 – 8.68 | |||
| Organ System Involvement (present/absent) | |||||
| Lung | 2.39 | 1.29 – 4.44 | 0.006 | ||
| Renal crisis | 1.63 | 0.80 – 3.31 | 0.17 | ||
| Cardiac | 2.93 | 1.55 – 5.53 | 0.0009 | ||
| Gastrointestinal tract | 2.14 | 1.17 – 3.93 | 0.01 | ||
| Joint/tendon | 1.00 | ||||
| Skeletal muscle | 1.49 | 0.50 – 4.43 | 0.47 | ||
| Pulmonary hypertension | 1.76 | 0.16 – 19.71 | 0.65 | ||
| Modified Medsger severity score | |||||
| Interstitial lung disease | none | 0.001 | |||
| mild/moderate | 1.51 | 0.71 – 3.20 | |||
| severe/endstage | 5.44 | 2.17 – 13.61 | |||
| Gastrointestinal tract | none | 0.001 | |||
| mild/moderate | 1.59 | 0.78 – 3.27 | |||
| severe/endstage | 4.07 | 1.92 – 8.62 | |||
| Joint/tendon | none | -- | 0.74 | ||
| mild/moderate | 0.91 | 0.28 – 2.93 | |||
| severe/endstage | 1.23 | 0.34 – 4.33 | |||
| Skeletal muscle | none | < 0.0001 | |||
| mild/moderate | 2.05 | 1.01 – 4.12 | |||
| severe/endstage | 7.57 | 2.96 – 19.34 | |||
| Peripheral vascular | none | 0.66 | |||
| mild | 1.23 | 0.53 – 2.82 | |||
| moderate | 1.36 | 0.65 – 2.83 | |||
| severe/endstage | 1.71 | 0.70 – 4.17 | |||
| Skin | none | 0.16 | |||
| mild | 0.88 | 0.35 – 2.17 | |||
| moderate | 1.17 | 0.43 – 3.21 | |||
| severe | 2.06 | 0.78 – 5.44 | |||
*
ESR:greater than age/2 for males or greater than age + 10 years/2 for females
Hgb = hemoglobin in mg/dL